OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades

OptimizeRx Corp (NASDAQ:OPRX) is one of the best performing micro cap stocks in 2025. On January 5, Stifel Nicolaus analyst David Grossman reaffirmed a Buy rating on OptimizeRx with a $21 price target. Just days earlier, on December 23, Lake Street analyst Eric Martinuzzi also reiterated a Buy rating on the stock, setting a $24 price target.

On December 17, OptimizeRx Corp (NASDAQ:OPRX) revealed a major expansion of its point-of-care network, which it said is aimed at boosting reach and engagement in clinical workflows.

The move involves four new agreements: first, an exclusive multi-year deal with a sought-after e-prescribing platform. OptimizeRx stated that this platform was once exclusive to a rival network, and bringing it into its fold widens access during prescription processes. Second, a fresh partnership introduces coverage in the point-of-discharge phase. This will allow interactions with providers right as patient treatment plans and instructions are set. OptimizeRx sees this as an opportunity to extend its presence beyond traditional settings.

Third and fourth, there will be multi-year renewals with two top-performing electronic health records and e-prescribing partners. One is now exclusive, lock in premium ad inventory and build on proven high returns for pharmaceutical clients, the company explained.

These steps add two new channel partners, a competitive eRx platform and a health systems access provider. As a result, OptimizeRx expects a 37% jump in unique National Provider Identifier reach.

Overall, the company’s management hopes that the expansions will strengthen its market edge in three ways. First, by securing exclusive spots, and then improving revenue predictability from established channels. Third, the expansions will support life sciences firms in driving faster brand uptake through in-workflow tools.

OptimizeRx Corp (NASDAQ:OPRX) is a digital health company. It provides point-of-care technology solutions to connect life sciences companies, healthcare providers, and patients. Its platform integrates real-time communication tools into electronic health records.

While we acknowledge the potential of OPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Must-Buy AI Stocks to Invest In and 11 Best NYSE Stocks Under $5 to Buy.

Disclosure: None. This article is originally published at Insider Monkey.